Sound waves zap kidney fat to lower blood pressure
NCT ID NCT06018493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed trial tested a new, noninvasive device that uses focused ultrasound to destroy a small amount of fat around the kidney. The goal was to lower blood pressure in people with mild hypertension who were not taking medication. 79 participants were randomly assigned to receive either the real ultrasound or a sham procedure, and their blood pressure was monitored over one to three months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- focused power ultrasound device
- What this could lead to
- If successful, this could offer a noninvasive, drug-free option to lower blood pressure in people with mild hypertension.
- What could go wrong
- This is a small, early-stage trial with only 79 participants. The effects may be modest or not last long, and the procedure carries risks like tissue damage or temporary discomfort.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
79 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Individual with office systolic blood pressure (SBP) ≥ 140 mmHg and \<160 mmHg, and diastolic blood pressure\<100mmHg when not taking antihypertensive drugs for at least 1 month; 2. Individual with 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP≥130 mmHg; 3. The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm; 4. Individual is willing to sign the informed consent of the study. Exclusion Criteria: 1. Individual with office systolic blood pressure (SBP) ≥ 160 mmHg and/or office diastolic blood pressure(DBP)≥ 100mmHg; 2. Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome); 3. Individuals with ≥ 3 cardiovascular risk factors (male\>55 years old, female\>65 years old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol/L and/or impaired fasting glucose (6.1-6.9mmol/L); LDL-C ≥ 3.4mmol/L (130mg/dl), HDL-C\<1.0mmol/L (40mg/dl) or TC ≥ 5.2mmol/L (200mg/dl); Family history of early onset of cardiovascular disease, age of onset of first degree relatives\<50 years old; Abdominal obesity, waist circumference: male≥90cm, female≥85cm or BMI≥28kg/m2) or hypertensive target organ damage; 4. Individuals taking other medications that may affect blood pressure (such as glucocorticoids); 5. Individual with history of kidney or kidney surrounding tissue surgery; 6. Individuals with impairment of liver or kidney function (ALT, AST or creatinine greater than 2 times of the upper limit of normal reference); 7. Individual with myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment; 8. Individual with type 1 diabetes or uncontrolled type 2 diabetes; 9. Individual with uncontrolled thyroid dysfunction; 10. Individual with urinary calculi or hematuria; 11. Individual with atrial fibrillation; 12. Individual with severe structural heart disease (e.g. valvular heart disease, cardiomyopathy, congenital heart disease); 13. Individual with second degree and above atrioventricular block and/or sick sinus syndrome; 14. Individual with abnormal coagulation function; 15. Individual with infected waist skin; 16. Individual with malignant tumor; 17. Individual is pregnant, nursing or planning to be pregnant; 18. Individual is unwilling to sign informed consent; 19. Individual fails to complete the screening period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Blood pressure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Province Hospital/The Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210000, China
-
Suzhou Municipal Hospital
Suzhou, Jiangsu, 215000, China
-
The Affiliated Jiangning Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210000, China
-
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Can pressing six points on the body help older adults sleep?
- Two eggs a day put to the test for heart health
- A soft patch that watches your heart beat in real time
- Can a vegan diet shield police officers from heart disease?
- Can a Plant-Based diet program help patients lose weight and improve heart health?